This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy


The prevalence of T790M acquired resistance mutation in patients treated with XOVOLTIB® is similar to first-generation TKIs3

Patients receiving a third-generation EGFR TKI following XOVOLTIB® treatment had an improved OS benefit versus gefitinib1

 

  • Around 50% of patients who progress on XOVOLTIB® have an acquired T790M mutation3
  • In LUX-Lung 7, the same percentage of patients in the XOVOLTIB® and gefitinib arms received a subsequent third-generation EGFR TKI (13.7% and 15.2%, respectively)2
  • Hazard ratio for OS suggested an improvement in favour of XOVOLTIB® versus gefitinib in patients who received a third-generation EGFR TKI with median OS not reached in the XOVOLTIB® arm and 46.0 months in the gefitinib arm (HR=0.51; 95% CI, 0.17–1.52; P=0.22)2

No difference in the proportion of XOVOLTIB®–treated patients receiving subsequent therapies after 1st-line therapy1
 

  • XOVOLTIB® OS benefit in del19 patients is not attributable to follow-up treatment1
  • In LUX-Lung 7, 73% of XOVOLTIB®–treated patients received subsequent therapy with chemotherapy and 46% with an EGFR TKI2
  • In LUX-Lung 3, 75% of chemotherapy-treated and 71% of XOVOLTIB®–treated patients received subsequent therapy with an EGFR TKI or chemotherapy,respectively1

TKI=tyrosine kinase inhibitor; OS=overall survival; EGFR =epidermal growth factor receptor

Is this information compelling to you?

References

  1. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.
  2. Paz-Arez L et al. Ann Oncol. 2017; 28(2):270-277
  1. [1] Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. [2] Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. [3] Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. [4] Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. [5] Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. [6] Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. [7] Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. [8] Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. [9] Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. [10] Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. [11] Paz-Arez L et al. Ann Oncol. 2017; 28(2):270-277

  12. [12] XOVOLTIB® Local pack insert version dated 21st July 2017

In case you come across any adverse events related to our products, please report it to PV team immediately.
Phone: +91 9819241697
Email: PV_local_India@boehringer-ingelheim.com

For any query on Boehringer Ingelheim India's product or therapy area, kindly contact
Phone: 1800227887
Email: medical.query.mum@boehringer-ingelheim.com

Back to top